ENHANCEMENT OF THERAPEUTIC ACTION OF ANTI-HYPERLIPIDEMIC DRUGS BY USING A NOVEL NANOSUSPENSION-BASED APPROACH

Hyperlipidemia is an elevated condition of lipid levels in the body and is known to speed up a process of atherosclerosis that may prove fatal in the development of various cardiovascular diseases. The figures of the patient with hyperlipidemia are constantly increasing which is rising a serious risk factor for a group of cardiovascular diseases. Although various pharmacotherapy for hyperlipidemia namely statins, niacin, fibric acid derivatives, cholesterol absorption inhibitors, and bioactive are available but suffer from various hurdles such as inadequate solubility and poor absorption leading to low bioavailability and ineffectiveness in lowering of cholesterol levels only up maximum 40%. Hence it is required to combat these hurdles associated with hyperlipidemia. Nanotechnology has provided revolutionary changes in medicine, providing a novel approach to treating hyperlipidemia. Various nanotechnology-based approaches include nanosuspension, nanoemulsion, nanoparticle, polymeric nanoparticle, dendrimer, polymeric micelle, etc. out of which nanosuspension has provided a strong background to combat the hurdles linked with pharmacotherapy due to possession of various benefits such as improved aqueous solubility, enhanced bioavailability, fast onset of action, reduced dosing regimen, enhanced dosing frequency, easy to prepare to contribute overall to patient compliance. Hence, this review provides deep knowledge about pharmacotherapy, bioactive used in hyperlipidemia, hurdles associated with drugs used in hyperlipidemia, the requirement of nanosuspension to combat these hurdles, recent research on nanoemulsion for anti-hyperlipidemic drugs along with patents and marketed formulations.